Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer

BACKGROUND. nab-Paclitaxel in combination with gemcitabine has emerged as a new treatment option for patients with metastatic pancreatic cancer (MPC), based on superiority over gemcitabine demonstrated in the phase III MPACT trial. Previously, Karnofsky performance status (KPS) score and the presenc...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Tabernero, Josep, Chiorean, E. Gabriela, Infante, Jeffrey R., Hingorani, Sunil R., Ganju, Vinod, Weekes, Colin, Scheithauer, Werner, Ramanathan, Ramesh K., Goldstein, David, Penenberg, Darryl N., Romano, Alfredo, Ferrara, Stefano, Von Hoff, Daniel D.
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2015
Assuntos:
Gastrointestinal Cancer
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4319641/
https://ncbi.nlm.nih.gov/pubmed/25582141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0394
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares